Substituted pyridine and pyrimidine derivatives and their use in treating viral infections

US9433621B2 · kind B2 · utility

Assignees

• Merck Sharp & Dohme LLC · US
• Southern Research Institute · US

Inventors

• Ashok Arasappan · Bound Brook, US
• F. George Njoroge · Hackettstown, US
• Cecil D. Kwong · Decatur, US
• Subramaniam Ananthan · Birmingham, US
• Frank Bennett · Piscataway, US
• Francisco Velazquez · Clinton, US
• Vinay M. Girijavallabhan · Woburn, US
• Yuhua Huang · Westfield, US
• Hollis S. Kezar, III · Hoover, US
• Joseph A. Maddry · Birmingham, US
• Robert C. Reynolds · Birmingham, US
• Abhijit Roychowdhury · Birmingham, US
• Anita T. Fowler · Irondale, US
• John A. Secrist, III · Birmingham, US
• Joseph A. Kozlowski · Princeton, US
• Bandarpalle B. Shankar · Readington, US
• Ling Tong · Hackettstown, US
• Seong Heon Kim · Livingston, US
• Malcolm MacCoss · Freehold, US
• Srikanth Venkatraman · Fords, US
• Vishal Verma · San Francisco, US

Key dates

• Filing date: Feb 18, 2011
• Grant date: Sep 6, 2016
• Expiry date: Jan 11, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D513/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides compounds of Formula (I): and tautomers, isomers, and esters of said compounds, and pharmaceutically acceptable salts, solvates, and prodrugs of said compounds, wherein each of R, R1, X, Y, Z, R2, R3, R4, R5, R6, R7, R8, R9, R18, R19 and n is selected independently and as defined herein. Compositions comprising such compounds are also provided. The compounds of the invention are effective as inhibitors of HCV, and are useful, alone and together with other therapeutic agents, in treating or preventing diseases or disorders such as viral infections and virus-related disorders.